Sponsor or institution

Clinical trials and research at InxMed (Shanghai) Co., Ltd.

• 7Clinical trials
• 1Country

Newest trials

All recruiting trials (7)

• IN10018 plus RNK08954 for KRASG12D-positive advanced solid tumors

  This trial will test whether combining IN10018 with RNK08954 can shrink tumors or control disease in people with KRASG12D-mutated locally advanced or metastatic solid tumors, with enrollment focused on pancreatic cancer.

  Recruiting Phase 1/2 InxMed (Shanghai) Co., Ltd. · Beijing, Beijing Municipality and 13 other locations · NCT07441174

• IN10018 plus D-1553 versus anti-PD-1 and chemotherapy for first-line KRAS G12C non-squamous NSCLC

  This trial tests whether taking IN10018 with D-1553 works better than standard anti‑PD‑1 plus platinum and pemetrexed for people with newly diagnosed, advanced non‑squamous NSCLC that has a KRAS G12C mutation.

  Recruiting at 8 sites Phase 3 InxMed (Shanghai) Co., Ltd. · Beijing, Beijing Municipality and 10 other locations · NCT07174908

• Combination therapy for treatment-naïve extensive stage small cell lung cancer

  This study is testing a new combination of treatments for people with extensive-stage small cell lung cancer to see if it works better than the usual options.

  Recruiting Phase 1/2 InxMed (Shanghai) Co., Ltd. · Jinan and 2 other locations · NCT06030258

• Treatment for platinum-resistant recurrent ovarian cancer using IN10018 and PLD

  This study is testing whether a new treatment combining IN10018 with a standard cancer drug can help people with platinum-resistant recurrent ovarian cancer feel better compared to a placebo.

  Recruiting Phase 2 InxMed (Shanghai) Co., Ltd. · Beijing · NCT06014528

• Combination therapy for advanced lung cancer with specific mutations

  This study is testing a new combination treatment for advanced lung cancer patients with specific mutations to see if it helps shrink tumors and is safe to use.

  Recruiting Phase 1/2 InxMed (Shanghai) Co., Ltd. · Shanghai · NCT05994131

• Combination of IN10018 and standard chemotherapy for advanced pancreatic cancer

  This study is testing if a new drug called IN10018, when combined with standard chemotherapy, can help people with advanced pancreatic cancer feel better and improve their treatment results.

  Recruiting Phase 1/2 InxMed (Shanghai) Co., Ltd. · Shanghai, Shanghai Municipality · NCT05827796

• Combining IN10018 with standard chemotherapy for advanced ovarian cancer

  This study is testing if adding a new drug called IN10018 to standard chemotherapy can help people with advanced ovarian cancer that hasn't responded to other treatments.

  Recruiting at 7 sites Phase 1/2 InxMed (Shanghai) Co., Ltd. · Anyang and 6 other locations · NCT05551507

Quick answers

How many clinical trials run by InxMed (Shanghai) Co., Ltd. are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 5, Phase 2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →